This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
All You Need to Know About Quanterix (QTRX) Rating Upgrade to Buy
by Zacks Equity Research
Quanterix (QTRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down 24.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Quanterix (QTRX)
by Zacks Equity Research
Quanterix (QTRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Quanterix Corporation (QTRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Quanterix (QTRX) delivered earnings and revenue surprises of -14.63% and -12.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Exagen (XGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix (QTRX) delivered earnings and revenue surprises of 23.19% and 8.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Phibro Animal Health (PAHC) Q3 Earnings Beat Estimates
by Zacks Equity Research
Phibro (PAHC) delivered earnings and revenue surprises of 21.15% and 0.78%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zynex (ZYXI) delivered earnings and revenue surprises of -122.22% and 14.39%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioLife Solutions (BLFS) delivered earnings and revenue surprises of 83.33% and 6.29%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
QuantumSi Set to Report Q4 Earnings: Buy, Sell or Hold the Stock?
by Nilanshi Mukherjee
QSI's fourth-quarter performance is expected to have benefited from year-end capital spending and new product launches despite competition and stretched valuation.
Zimmer Biomet (ZBH) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 0.43% and 0.53%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Cresco Labs Inc. (CRLBF) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -100% and 2.94%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
InMode (INMD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
InMode (INMD) delivered earnings and revenue surprises of 22.81% and 0.18%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Brainsway (BWAY) Soars 14.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Brainsway (BWAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Quanterix Corporation (QTRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix (QTRX) delivered earnings and revenue surprises of -8.70% and 0.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 22.73% and 2.34%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Ayr Wellness Inc. (AYRWF) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Quanterix Corporation (QTRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Quanterix (QTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Quanterix (QTRX) Could Rally 67.66%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 67.7% upside potential for Quanterix (QTRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix (QTRX) delivered earnings and revenue surprises of 21.21% and 1.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
by Zacks Equity Research
Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.
Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of -17.86% and 13.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances
by Zacks Equity Research
Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.
Here's Why Quanterix Corporation (QTRX) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Quanterix Corporation (QTRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Quanterix Corporation (QTRX) Have the Potential to Rally 33.74% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Quanterix Corporation (QTRX) points to a 33.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 54.88% Upside in Quanterix Corporation (QTRX): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Quanterix Corporation (QTRX) points to a 54.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.